Classical Motor Features of Parkinson’s Disease

Parkinson's Disease

Volumn , Issue , 2004, Pages 171-181

  Chou, Kelvin L ^a   Hurtig, Howard I ^b  

^a BROWN UNIVERSITY   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85160149935     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-26     Document Type: Chapter

References (103)

1. Parkinson, J., An Essay on the Shaking Palsy, Sherwood, Neely, and Jones, London, 1817.
2. Colcher, A. and Simuni, T., Clinical manifestations of Parkinson’s disease, Med. Clin. North Am., 83, 327, 1999.
3. Dickson, D. W., Neuropathology of parkinsonian disorders, in Parkinson’s Disease and Movement Disorders, 4th ed., Jankovic, J. J. and Tolosa, E., Eds., Lippincott Williams & Wilkins, Philadelphia, 2002, 256.
4. Calne, D. B., Snow, B. J., and Lee, C., Criteria for diagnosing Parkinson’s disease, Ann. Neurol., 32 Suppl, S125, 1992.
5. Gelb, D. J., Oliver, E., and Gilman, S., Diagnostic criteria for Parkinson disease, Arch Neurol, 56, 33, 1999.
6. Hughes, A. J. et al., Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases, J Neurol. Neurosurg. Psychiatry, 55, 181, 1992.
7. Langston, J. W. et al., Core assessment program for intracerebral transplantations (CAPIT), Mov. Disord., 7, 2, 1992.
8. Ward, C. D. and Gibb, W. R., Research diagnostic criteria for Parkinson’s disease, Adv. Neurol., 53, 245, 1990.
9. Rajput, A. H., Rozdilsky, B., and Rajput, A., Accuracy of clinical diagnosis in parkinsonism—a prospective study, Can. J. Neurol. Sci., 18, 275, 1991.
10. Hughes, A. J., Daniel, S. E., and Lees, A. J., Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease, Neurology, 57, 1497, 2001.
11. Hurtig, H. I. et al., Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease, Neurology, 54, 1916, 2000.
12. Hughes, A. J. et al., What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathologic study, Neurology, 42, 1142, 1992.
13. Edwards, L. L., Quigley, E. M., and Pfeiffer, R. F., Gastrointestinal dysfunction in Parkinson’s disease: Frequency and pathophysiology, Neurology, 42, 726, 1992.
14. Lee, C. S. et al., Patterns of asymmetry do not change over the course of idiopathic parkinsonism: Implications for pathogenesis, Neurology, 45, 435, 1995.
15. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease, N. Engl. J. Med., 345, 956, 2001.
16. Burchiel, K. J. et al., Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson’s disease: Results of a randomized, blinded pilot study, Neurosurgery, 45, 1375, 1999.
17. Deuschl, G., Bain, P., and Brin, M., Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee, Mov. Disord., 13, suppl. 3, 2, 1998.
18. Hoehn, M. M. and Yahr, M. D., Parkinsonism: Onset, progression and mortality, Neurology, 17, 427, 1967.
19. Hughes, A. J., Daniel, S. E., and Lees, A. J., The clinical features of Parkinson’s disease in 100 histologically proven cases, Adv. Neurol., 60, 595, 1993.
20. Martin, W. E. et al., Parkinson’s disease. Clinical analysis of 100 patients, Neurology, 23, 783, 1973.
21. Louis, E. D. et al., Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson’s disease, Neurology, 48, 376, 1997.
22. Lance, J. W., Schwarb, R. S., and Peterson, E. A., Action tremor and the cogwheel phenomenon in Parkinson’s disease, Brain, 86, 95, 1963.
23. Scott, R. M. et al., Progression of unilateral tremor and rigidity in Parkinson’s disease, Neurology, 20, 710, 1970.
24. Djaldetti, R. et al., Camptocormia (bent spine) in patients with Parkinson’s disease—characterization and possible pathogenesis of an unusual phenomenon, Mov Disord, 14, 443, 1999.
25. Cotzias, G. C., Van Woert, M. H., and Schiffer, L. M., Aromatic amino acids and modification of parkinsonism, N. Engl. J. Med., 276, 374, 1967.
26. Yahr, M. D. et al., Treatment of parkinsonism with levodopa, Arch. Neurol., 21, 343, 1969.
27. Comella, C. L. et al., Physical therapy and Parkinson’s disease: A controlled clinical trial, Neurology, 44, 376, 1994.
28. Zesiewicz, T. A. and Hauser, R. A., Phenomenology and treatment of tremor disorders, Neurol. Clin., 19, 651, 2001.
29. Hunker, C. J. and Abbs, J. H., Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue, and index finger, Mov. Disord., 5, 71, 1990.
30. Findley, L. J., Gresty, M. A., and Halmagyi, G. M., Tremor, the cogwheel phenomenon and clonus in Parkinson’s disease, J. Neurol Neurosurg. Psychiatry, 44, 534, 1981.
31. Pal, P. K., Samii, A., and Calne, D. B., Cardinal features of early Parkinson’s disease, in Parkinson’s Disease: Diagnosis and Clinical Management, Factor, S. A. and Weiner, W. J., Eds., Demos Medical Publishing, Inc., New York, 41, 2002.
32. Shulman, L. M. et al., Internal tremor in patients with Parkinson’s disease, Mov. Disord., 11, 3, 1996.
33. Askenasy, J. J. and Yahr, M. D., Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep, J. Neurol. Neurosurg. Psychiatry, 53, 749, 1990.
34. Rajput, A. H., Rozdilsky, B., and Ang, L., Occurrence of resting tremor in Parkinson’s disease, Neurology, 41, 1298, 1991.
35. Wasielewski, P. G., Burns, J. M., and Koller, W. C., Pharmacologic treatment of tremor, Mov. Disord., 13, suppl. 3, 90, 1998.
36. Koller, W. C., Pharmacologic treatment of parkinsonian tremor, Arch Neurol, 43, 126, 1986.
37. Koller, W. C. and Herbster, G., Adjuvant therapy of parkinsonian tremor, Arch. Neurol., 44, 921, 1987.
38. Friedman, J. H. et al. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease, Neurology, 48, 1077, 1997.
39. Pogarell, O. et al., Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: A randomised, double blind, placebo controlled multicentre study, J. Neurol. Neurosurg. Psychiatry, 72, 713, 2002.
40. Schrag, A., Keens, J., and Warner, J., Ropinirole for the treatment of tremor in early Parkinson’s disease, Eur. J. Neurol., 9, 253, 2002.
41. Krack, P. et al., Treatment of tremor in Parkinson’s disease by subthalamic nucleus stimulation, Movement Disorders, 13, 907, 1998.
42. Rodriguez, M. C. et al., The subthalamic nucleus and tremor in Parkinson’s disease, Mov. Disord., 13, suppl. 3, 111, 1998.
43. Benabid, A. L. et al., Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders, J. Neurosurg., 84, 203, 1996.
44. Koller, W. et al., High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor, Ann. Neurol., 42, 292, 1997.
45. Maher, E. R. and Lees, A. J., The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy), Neurology, 36, 1005, 1986.
46. Koller, W. C. et al., Falls and Parkinson’s disease, Clin. Neuropharmacol., 12, 98, 1989.
47. de Rijk, M. C. et al., Prevalence of parkinsonism and Parkinson’s disease in Europe: The EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease, J Neurol. Neurosurg. Psychiatry, 62, 10, 1997.
48. Moghal, S. et al., Prevalence of movement disorders in elderly community residents, Neuroepidemiology, 13, 175, 1994.
49. Van Den Eeden, S. K. et al., Incidence of Parkinson’s disease: Variation by age, gender, and race/ethnicity, Am J. Epidemiol., 157, 1015, 2003.
50. Zetusky, W. J., Jankovic, J., and Pirozzolo, F. J., The heterogeneity of Parkinson’s disease: Clinical and prognostic implications, Neurology, 35, 522, 1985.
51. Jankovic, J. et al., Variable expression of Parkinson’s disease: A base-line analysis of the DATATOP cohort. The Parkinson Study Group, Neurology, 40, 1529, 1990.
52. Golbe, L. I., Young-onset Parkinson’s disease: A clinical review, Neurology, 41, 168, 1991.
53. Yokochi, M. et al., Juvenile parkinsonism—some clinical, pharmacological, and neuropathological aspects, Adv. Neurol., 40, 407, 1984.
54. Quinn, N., Critchley, P., and Marsden, C. D., Young onset Parkinson’s disease, Mov. Disord., 2, 73, 1987.
55. Gibb, W. R. and Lees, A. J., A comparison of clinical and pathological features of youngand old-onset Parkinson’s disease, Neurology, 38, 1402, 1988.
56. Takahashi, H. et al., Familial juvenile parkinsonism: Clinical and pathologic study in a family, Neurology, 44, 437, 1994.
57. Muthane, U. B. et al., Early onset Parkinson’s disease: Are juvenileand young-onset different?, Mov. Disord., 9, 539, 1994.
58. Fearnley, J. M. and Lees, A. J., Ageing and Parkinson’s disease: Substantia nigra regional selectivity, Brain, 114 (Pt. 5), 2283, 1991.
59. Marek, K. L. et al., [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease, Neurology, 46, 231, 1996.
60. Gonera, e.g., et al., Symptoms and duration of the prodromal phase in Parkinson’s disease, Mov. Disord., 12, 871, 1997.
61. Poewe, W. H., Lees, A. J., and Stern, G. M., Dystonia in Parkinson’s disease: Clinical and pharmacological features, Ann. Neurol., 23, 73, 1988.
62. Schenck, C. H., Bundlie, S. R., and Mahowald, M. W., Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder, Neurology, 46, 388, 1996.
63. Doty, R. L., Deems, D. A., and Stellar, S., Olfactory dysfunction in parkinsonism: A general deficit unrelated to neurologic signs, disease stage, or disease duration, Neurology, 38, 1237, 1988.
64. Doty, R. L., Shaman, P., and Dann, M., Development of the University of Pennsylvania Smell Identification Test: A standardized microencapsulated test of olfactory function, Physiol. Behav., 32, 489, 1984.
65. Schrag, A. et al., Young-onset Parkinson’s disease revisited—clinical features, natural history, and mortality, Mov. Disord., 13, 885, 1998.
66. Calne, D. B., Parkinson’s disease is not one disease, Parkinsonism Related Disord., 7, 3, 2000.
67. Birkmayer, W., Riederer, P., and Youdim, B. H., Distinction between benign and malignant type of Parkinson’s disease, Clin. Neurol. Neurosurg., 81, 158, 1979.
68. Goetz, C. G. et al., Risk factors for progression in Parkinson’s disease, Neurology, 38, 1841, 1988.
69. Kostic, V. et al., Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease, Neurology, 41, 202, 1991.
70. Mortimer, J. A. et al., Relationship of motor symptoms to intellectual deficits in Parkinson disease, Neurology, 32, 133, 1982.
71. Hershey, L. A. et al., Tremor at onset. Predictor of cognitive and motor outcome in Parkinson’s disease?, Arch. Neurol., 48, 1049, 1991.
72. Wichmann, T. and DeLong, M. R., Functional neuroanatomy of the basal ganglia in Parkinson’s disease, Adv. Neurol., 91, 9, 2003.
73. Bergman, H. et al., Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates, Trends Neurosci., 21, 32, 1998.
74. Kutukcu, Y. et al., Simple and choice reaction time in Parkinson’s disease, Brain Research, 815, 367, 1999.
75. Evarts, E. V., Teravainen, H., and Calne, D. B., Reaction time in Parkinson’s disease, Brain, 104, 167, 1981.
76. Berardelli, A. et al., Pathophysiology of bradykinesia in Parkinson’s disease, Brain, 124, 2131, 2001.
77. Hallett, M., Parkinson revisited: Pathophysiology of motor signs, Advances in Neurology, 91, 19, 2003.
78. Chen, R. et al., Impairment of motor cortex activation and deactivation in Parkinson’s disease, Clin Neurophysiol, 112, 600, 2001.
79. Pascual-Leone, A. et al., Akinesia in Parkinson’s disease. I. Shortening of simple reaction time with focal, single-pulse transcranial magnetic stimulation, Neurology, 44, 884, 1994.
80. Jenkins, I. H. et al., Impaired activation of the supplementary motor area in Parkinson’s disease is reversed when akinesia is treated with apomorphine, Ann. Neurol., 32, 749, 1992.
81. Ceballos-Baumann, A. O. et al., Restoration of thalamocortical activity after posteroventral pallidotomy in Parkinson’s disease, Lancet, 344, 814, 1994.
82. Benecke, R. et al., Disturbance of sequential movements in patients with Parkinson’s disease, Brain, 110 (Pt. 2), 361, 1987.
83. Benecke, R. et al., Performance of simultaneous movements in patients with Parkinson’s disease, Brain, 109 (Pt. 4), 739, 1986.
84. Brown, R. G. and Marsden, C. D., Dual task performance and processing resources in normal subjects and patients with Parkinson’s disease, Brain, 114, 215, 1991.
85. Hallett, M. and Khoshbin, S., A physiological mechanism of bradykinesia, Brain, 103, 301, 1980.
86. Berardelli, A. et al., Scaling of the size of the first agonist EMG burst during rapid wrist movements in patients with Parkinson’s disease, Journal of Neurology, Neurosurgery & Psychiatry, 49, 1273, 1986.
87. Dietz, V., Quintern, J., and Berger, W., Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia, Brain, 104, 431, 1981.
88. Watts, R. L., Wiegner, A. W., and Young, R. R., Elastic properties of muscles measured at the elbow in man: II. Patients with parkinsonian rigidity, J. Neurol. Neurosurg. Psychiatry, 49, 1177, 1986.
89. Rothwell, J. C. et al., The behaviour of the long-latency stretch reflex in patients with Parkinson’s disease, Journal of Neurology, Neurosurgery & Psychiatry, 46, 35, 1983.
90. Tatton, W. G. and Lee, R. G., Evidence for abnormal long-loop reflexes in rigid Parkinsonian patients, Brain Research, 100, 671, 1975.
91. Hayashi, R. et al., Relation between changes in longlatency stretch reflexes and muscle stiffness in Parkinson’s disease—comparison before and after unilateral pallidotomy, Clin. Neurophysiol., 112, 1814, 2001.
92. Young, M. S. et al., Stereotactic pallidotomy lengthens the transcranial magnetic cortical stimulation silent period in Parkinson’s disease, Neurology, 49, 1278, 1997.
93. Rothwell, J. C., Physiology and anatomy of possible oscillators in the central nervous system, Mov. Disord., 13, suppl. 3, 24, 1998.
94. Carr, J., Tremor in Parkinson’s disease, Parkinsonism Relat. Disord., 8, 223, 2002.
95. Otsuka, M. et al., Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson’s disease: Correlations with the three main symptoms, Journal of the Neurological Sciences, 136, 169, 1996.
96. Hedreen, J. C., Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus, J. Comp. Neurol., 409, 400, 1999.
97. Lozano, A. M. et al., Effect of GPi pallidotomy on motor function in Parkinson’s disease, Lancet, 346, 1383, 1995.
98. Bergman, H. et al., The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism, J. Neurophysiol., 72, 507, 1994.
99. Bergman, H. and Deuschl, G., Pathophysiology of Parkinson’s disease: From clinical neurology to basic neuroscience and back, Mov. Disord., 17, suppl. 3, S28, 2002.
100. Deiber, M. P. et al., Thalamic stimulation and suppression of parkinsonian tremor. Evidence of a cerebellar deactivation using positron emission tomography, Brain, 116, 267, 1993.
101. Horak, F. B., Frank, J., and Nutt, J., Effects of dopamine on postural control in parkinsonian subjects: Scaling, set, and tone, J. Neurophysiol., 75, 2380, 1996.
102. Horak, F. B., Nutt, J. G., and Nashner, L. M., Postural inflexibility in parkinsonian subjects, J. Neurol. Sci., 111, 46, 1992.
103. Bronte-Stewart, H. M. et al., Postural instability in idiopathic Parkinson’s disease: The role of medication and unilateral pallidotomy, Brain, 125, 2100, 2002